One of the problems with intravenous administration of STING-Ls is their short half-life (especially in the case of 2′3′-cGAMP) due to their sensitivity to degradation by ENPP1.44 Packaging of 2′3′-cGAMP into liposomal nanoparticles improves its half-life, tumor penetration, and cellular uptake on intravenous injection, as compared with soluble cGAMP.42 On the other hand, new STING-Ls with enhanced cell permeability and resistance to hydrolysis by ENPP1 are being developed.45 It would be interesting to test these new STING-L formulations intravenously in combination with CART cells. Here, STING1 is linked to neoplasm.